Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

etoposide/vēzis

Saite tiek saglabāta starpliktuvē
Lappuse 1 no 39 rezultātiem
FIELD OF THE INVENTION The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers, and specifically relates to 4'-O-glycosyl-etoposides as prodrugs
FIELD OF THE INVENTION The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers, and specifically relates to 4'-O-glycosyl-etoposides as prodrugs
FIELD OF THE INVENTION The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers, and specifically relates to 4'-O-glycosyl-etoposides as prodrugs

Synthetic process for the preparation of anti-tumor agent-etoposide

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The present invention relates to a new synthetic process for the preparation of the anti-tumor agent etoposide. BACKGROUND OF THE INVENTION Etoposide (VP16-213), a semi-synthetic anti-tumor drug, is used effectively for the treatment of acute monocytic leukemia (Schilling's

Analogues of etoposide for the treatment of tumours

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
CROSS-REFERENCES TO RELATED APPLICATIONS This application is the U.S. National Stage of International Application No. PCT/EP2011/001960, filed Apr. 18, 2011, which designated the United States and has been published as International Publication No. WO 2011/128115 and which claims the priority of

Etoposide and prodrugs thereof for use in targeting cancer stem cells

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells (CSC). The invention discloses the surprisingly specific activity of the compounds in

Etoposide and prodrugs thereof for use in targeting cancer stem cells

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application of International Application Number PCT/EP2014/054785, filed Mar. 12, 2014; which claims priority to Great Britain Application No. 1304417.7, filed Mar. 12, 2013; both of which are incorporated herein by
The present invention relates to etoposide derivatives, to a process for preparing them and to their use as an anticancer medicinal product. Etoposide a and some of its derivatives such as teniposide b ##STR2## are known to have antitumor activities which are useful in human clinical medicine. They

Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes simplex virus

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
CROSS-REFERENCE TO RELATED APPLICATIONS The present application claims the benefit of priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application No. 61/133,478 filed Jun. 30, 2008. FIELD OF THE INVENTION The present application relates generally to a method of determining tumor cell

HDAC 6 inhibitor-based methods for treating cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains. BACKGROUND OF THE INVENTION Histone acetylation is a reversible

Inhalation-type pharmaceutical composition for the treatment of lung cancer and preparation method thereof

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
PRIORITY CLAIM This application claims the benefit of the filing date of Taiwan Patent Application No. 103114133, filed Apr. 18, 2014, entitled "INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LUNG CANCER AND PREPARATION METHOD THEREOF," and the contents of which are hereby

Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD OF THE INVENTION The present invention relates to a novel method for the delivery of cytotoxic agents to tumor cells by the combined use of antibody-enzyme conjugates and prodrugs. More particularly, this invention relates to a method for the delivery of cytotoxic drugs to the site

Anti-cancer combinations

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The invention relates to compositions comprising combinations of anti-cancer drugs and methods of using the compositions for the the treatment of cancer. BACKGROUND 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is represented by the following formula: ##STR00001## Phase I

Anti-cancer combinations

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The invention relates to compositions comprising combinations of anti-cancer drugs and methods of using the compositions for the treatment of cancer. BACKGROUND 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is represented by the following formula: ##STR00001## Phase I clinical

Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This application is the U.S. National Phase of, and Applicants claim priority from, International Application Number PCT/CU2007/000010 filed 28 Feb. 2007 and Cuban Application bearing Serial No. CU 2006-0049 filed 28 Feb. 2006, which are incorporated herein by reference. TECHNICAL FIELD The present
Pievienojieties mūsu
facebook lapai

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

  • Darbojas 55 valodās
  • Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
  • Garšaugu atpazīšana pēc attēla
  • Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
  • Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
  • Meklēt ārstniecības augus pēc to iedarbības
  • Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem

Google Play badgeApp Store badge